NovoCare Pharmacy Review: The Only Seller Whose Peptide Has an NDC — and a Banner It Cannot Support

NovoCare Pharmacy is not a pharmacy

The name is a program, not an entity. Working out who actually fills the prescription takes a trip to the terms, and the terms are unusually forthcoming once you get there.

Three companies are disclosed by name. AssistRx runs patient intake and the benefits investigation. CoAssist Pharmacy, LLC — "[a] licensed pharmacy in all 50 US states and territories that, for purposes of this program, is CoAssist Pharmacy d/b/a NovoCare® Pharmacy" — receives the prescription. And then: "These cash/self-pay prescriptions are filled by Centerwell® Pharmacy or CoAssist Pharmacy d/b/a NovoCare® Pharmacy." The home page carries the short version in footnote f: "CoAssist Pharmacy is a dispensing pharmacy for NovoCare® Pharmacy."

Name three third parties, including the one that touches your medicine, and you are ahead of almost everyone in this market. Two of the three other providers reviewed on this site will not name the compounding pharmacy that makes their peptides at all.

Where it stops short is the next step. CoAssist is a name and nothing else: no license number, no address, no link. On August 7, 2026, coassistpharmacy.com resolved in DNS but returned no response at all — a connection reset, not a holding page. Re-checked on August 26, 2026 it does answer, with 114 bytes: a script that redirects to `/lander`, a domain-parking page. That is a change in the failure mode rather than an improvement. So a patient handed the name of the company that will dispense their drug cannot look it up from the site that named it. The identifiers in this review — Florida community pharmacy license PH34564, listed Clear and running to February 28, 2027; a federal registration as a community/retail pharmacy at 2400 Sand Lake Rd Ste 200b, Orlando, Florida — came from the Florida Department of Health's license verification service and from NPPES, the federal provider registry. They are public, they check out, and none of them came from Novo Nordisk.

What the trials actually found, and which trial belongs to which product

The pharmacy defers to the label on efficacy, which is the correct behavior for a dispenser and leaves this review to do the evidence reporting itself. Three approved presentations, three distinct evidence bases, and they are not interchangeable.

The injectable semaglutide 2.4 mg sold as Wegovy rests on STEP 1: 1,961 adults with overweight or obesity, randomized to once-weekly semaglutide 2.4 mg or placebo for 68 weeks, published in the New England Journal of Medicine in March 2021. ^{1 2} That is the trial that reset expectations for what a peptide could do to body weight, and its registry record — phase 3, completed, enrollment 1,961 — is public and posted. ²

The tablets are a separate program. Oral semaglutide 25 mg was tested in OASIS 4: 307 adults, 64 weeks, phase 3, completed, results posted on ClinicalTrials.gov, published in the New England Journal of Medicine in September 2025. ³ Three hundred and seven participants is a sixth of STEP 1, and a reader should hold the two findings with correspondingly different confidence — but a separately tested oral presentation is still a categorically stronger position than an oral formulation of a peptide that has only ever been injected in a trial, which is what the compounded market routinely sells.

The 7.2 mg high-dose pen priced at $399 has its own trial too, STEP UP: 1,407 adults, phase 3b, completed, published in Lancet Diabetes & Endocrinology in November 2025. ⁵

And Ozempic, which the pricing table lists next to Wegovy as though the choice between them were about presentation, is approved for type 2 diabetes. Novo's terms are explicit that participation requires a prescription "for an FDA-approved indication." A reader arriving from a weight-loss search and choosing the cheaper-looking Ozempic pen is choosing a drug approved for something else. Both of those statements are on the site. They are not on the same page.

Two tablets, one molecule, different trials

The Ozempic pill, new to the pricing table since this review was first published, is where that distinction stops being a debating point and becomes a citation.

It is oral semaglutide. So is the Wegovy tablet. Same molecule, same dose form, same manufacturer, both sold from the same four-card grid — and they rest on different trial programs, because they are approved for different conditions. Oral semaglutide was tested for obesity in OASIS, and for type 2 diabetes in PIONEER. Ozempic is the diabetes brand, so PIONEER 1 is its evidence: 703 adults with type 2 diabetes managed on diet and exercise alone, randomized against placebo, phase 3, completed, results posted, published in Diabetes Care in 2019. ^{6 7} A companion trial, PIONEER 6, followed 3,183 people for cardiovascular safety — the question that matters most for a tablet taken every day for a chronic condition. ⁶

Citing OASIS here instead would have been the easiest mistake on this page to make, and nothing on the site would have caught it. What settles it is the identifier this review keeps calling the strongest thing NovoCare publishes. Look the two tablets up in FDA's own listing database and they come back under different applications: Ozempic tablets under NDA 213051, the oral semaglutide application it shares with Rybelsus, and Wegovy tablets under NDA 218316. ⁸

| | Wegovy® tablets | Ozempic® pill | |---|---|---| | Application | NDA 218316 | NDA 213051 | | Approved for | chronic weight management | type 2 diabetes | | Trial program | OASIS | PIONEER | | Strengths sold | 1.5, 4, 9, 25 mg | 1.5, 4, 9 mg | | Price ladder | $149 / $199 / $299 | $149 / $199 / $299 | | Introductory? | no end date published | no — printed as a standard offer |

Two things about that last row. The Ozempic pill is the only product NovoCare sells whose prices are not framed as a limited-time rate, which makes it, quietly, the most honestly priced thing on the page. And its ladder is not on the page: the footnote under the button says only that pricing "varies by dose", and the three figures live in a downloadable price guide. A reader who does not open it carries away $149 and no idea that 9 mg is $299.

One more small thing, offered as a check rather than an accusation. The whole argument for a National Drug Code is that anyone can look it up, so this review looked all seven tablet codes up. Six match. The seventh, the 4 mg Ozempic tablet, is printed in Novo's terms as 00169-1704-15, and FDA's directory has no such package — what it lists is 0169-1704-30, thirty tablets in one bottle. ⁸ That is a digit in a terms page, not a claim about a medicine. It is here because a number whose value is that it is checkable ought to be checked.

The pricing is honest and still needs decoding

Six footnotes, lettered a through f, sit under four buttons. They contain, between them, everything you need — which is more than most of this market offers — arranged so that the number you remember is the smallest one.

The pattern is the same throughout: a headline introductory rate, a stated number of fills, a date, and the figure it becomes. $199 a month buys the first two fills of Wegovy 0.25 mg or 0.5 mg through December 31, 2026, after which every strength from 0.25 mg to 2.4 mg is $349. Ozempic follows the injectable pattern, except that the 2 mg strength lands at $499 — 150 a month more than 1 mg of the same molecule, unexplained.

The tablets are where a reader has to be most careful, and where this review had to correct itself. The button says "Starting at $149 per month". Footnote a says what that starts from: $149 is 1.5 mg, 4 mg is $199, and 9 mg and 25 mg are $299. The 25 mg tablet is the one OASIS 4 tested — the trial this whole row rests on — so the evidence and the headline price belong to different strengths, and they differ by 150 a month.

An earlier version of this review printed $149 as the price of the 25 mg tablet, and reported the 4 mg step-up to $199 as still pending. Both are corrected here. The step-up has happened; the 9 mg and 25 mg rungs did not exist in the August read.

Two things are worth saying in the pharmacy's favor. The ongoing price is actually printed, with its date, which is the single most-omitted fact in this entire category. And the self-pay disclosure is unusually blunt: the tooltip states that by paying outside insurance, "any money spent will not count toward your out-of-pocket limits or deductible." That is a real cost, it is easy to leave out, and it has not been left out.

Where this sits against the rest of the market

The reason to review the manufacturer's own pharmacy on a site about peptides is that it establishes the ceiling. Everything about provenance that a compounded-peptide seller cannot give you, this can. The NDC of every presentation is printed in the terms, so the labeller, the product and the package size are all identifiable in FDA's own listing database by anyone who wants to check. The trials are registered, completed, published and posted. The dispensing pharmacies are named.

That ceiling is worth carrying to the other reviews on this site. When a seller of compounded sermorelin says its medication is "lab tested for quality and potency" but will not say which pharmacy compounded it, the gap between that and a printed NDC is the whole distance between a claim and a fact. Read what the evidence for semaglutide actually shows, and what it does not, before deciding that distance does not matter.

What this review cannot tell you is whether any of it is right for you, and it will not try. There is no prescriber here — the program dispenses against a prescription you obtain elsewhere, and the "connect with a prescriber" path hands you to third-party telehealth operating under practices Novo does not publish. That is a real gap in a chain that is otherwise the most legible in the category.